This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (23)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chronic idiopathic urticaria (CIU) is a troublesome disorder with an unknown etiological agent. Mast cell activation and release of mediators occur in all forms of urticaria. Although histamine is the principal inflammatory mediator of mast cell derivation, other mediators are freed after mast cell activation such as cysteinyl leukotrienes (leukotrienes C₄, D₄, and E₄).¹ We evaluate the efficacy and tolerability of an antileukotriene drug, montelukast sodium,² in relation to fexofenadine hydrochloride, an antihistaminic drug, in patients affected by CIU.

Study

Twenty-seven patients affected with CIU were selected; the 4 men and 23 women were aged between 20 and 74 years. The study was conducted for 30 days in double-blind fashion, dividing the patients into 2 groups: 15 took montelukast (10 mg/d), while the 12 patients in the control group took fexofenadine (180 mg/d). All patients underwent a skin test with autologous serum² and routine blood chemistry tests before . . . [Full Text of this Article]

Conclusions

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Montelukast Treatment of Urticaria
McBayne and Siddall
The Annals of Pharmacotherapy 2006;40:939-942.
ABSTRACT | FULL TEXT